T47D/S2 Cell Line
Invented by Dr Anne Lykkesfeldt at Danish Cancer Society
T47D-182R2 Cell Line
Invented by Dr Anne Lykkesfeldt from Danish Cancer Society
Invented at Danish Cancer Society
- Datasheet
- References (6)
- Inventor Info
Info
| Catalogue Number | 151890 |
| Antigen/Gene or Protein Targets | Oestrogen receptor |
| Parental Line | T47D |
| Host | Human |
| Tissue | Breast |
| Disease Keywords | Breast cancer, fulvestrant resistant |
| Model | Tumour line |
| Relevance | The T47D-182R2 Cell Line is a breast cancer cell line resistant to fulvestrant. Treatment with the steroidal antiestrogen fulvestrant has proven effective upon progression on tamoxifen therapy and is now approved for second-line treatment after tamoxifen or aromatase inhibitors. As for tamoxifen treatment of advanced breast cancer, resistance will inevitably occur also for fulvestrant. Clarification of the molecular changes associated with the resistant growth is needed to find targeted treatments to resistant tumour cells and treatments that can inhibit or delay the emergence of resistance. |
| Production Details | Human breast cancer cell line derived from T47D/S5 by long term treatment with 100 nM fulvestrant. |
| Research Area | Cancer, Drug Discovery & Development |
| Recommended Growing Conditions | Phenol red free RPMI 1640 + 5% FCS + glutamax + 8µg Insulin/ml + 100 nM fulvestrant. |
| Notes |
Grow with 5% feal calf serum and 100 nM fulvestrant. Estrogen and progesterone receptor negative. Passage 165 (AL3370, AL3384) |
| Cellosaurus ID | CVCL_1D35 |
References: 6 entries
Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Europe PMC ID: 25885472
SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Europe PMC ID: 25706943
Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.
Europe PMC ID: 24513268
Add a reference
References: 6 entries
Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.
Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.
Add a reference
